

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
30 September 2010 (30.09.2010)

(10) International Publication Number
WO 2010/110596 A2

(51) International Patent Classification:

C12N 5/071 (2010.01) C07K 14/475 (2006.01)
C12N 5/074 (2010.01) A61P 9/00 (2006.01)
C12N 5/02 (2006.01) A61L 27/38 (2006.01)

Su [KR/KR]; #103, 40-76 Hawolgok-dong, Seongbuk-gu, Seoul 136-130 (KR). **JUNG, Young Mee** [KR/KR]; Hanseong Heights #304, Gugi-dong, Jongno-gu, Seoul 110-011 (KR).

(21) International Application Number:

PCT/KR2010/001807

(74) Agents: **CHANG, Soo Kil** et al.; Kim & Chang, Seyang B/D, 223 Naeja-dong, Jongno-gu, Seoul 110-720 (KR).

(22) International Filing Date:

24 March 2010 (24.03.2010)

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10-2009-0024681 24 March 2009 (24.03.2009) KR
10-2010-0002149 11 January 2010 (11.01.2010) KR

(71) Applicant (for all designated States except US): **KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY** [KR/KR]; 39-1 Hawolgok-dong, Seongbuk-gu, Seoul 136-791 (KR).

(72) Inventors; and


(75) Inventors/Applicants (for US only): **KIM, Sang-Heon** [KR/KR]; Wolgok Raemian Apt. 111-101, 226 Hawolgok-dong, Seongbuk-gu, Seoul 136-130 (KR). **KIM, Soo Hyun** [KR/KR]; Sinbanpo 25-cha Apt. 345-706, Jamwon-dong, Seocho-gu, Seoul 137-951 (KR). **PARK, In**

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM,

[Continued on next page]

(54) Title: METHOD FOR DIFFERENTIATION OF STEM CELLS INTO VASCULAR CELLS AND THE INDUCTION OF ANGIOGENESIS USING THE SAME

[Fig. 13]



(57) Abstract: The present invention relates to a method for differentiating stem cells into vascular cells by culturing them in the form of a three-dimensional cell cluster and the use of the three-dimensional cell cluster for angiogenesis. Specifically, the present invention teaches a method for differentiating stem cells into vascular cells comprising culturing stem cells by adhering them onto a culture plate with a surface having a hydrophobic property or a culture plate onto which a growth factor is immobilized, wherein the cultured stem cells are later detached from the culture plate as their density increases to form a three-dimensional cell cluster and grown in the form of a three-dimensional cell cluster while differentiating into vascular cells. Also disclosed is the use of a three-dimensional cell cluster composed of the vascular cells differentiated from stem cells by the above method as a cell therapy agent for angiogenesis.

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, — *with sequence listing part of description (Rule 5.2(a))*
ML, MR, NE, SN, TD, TG).

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

METHOD FOR DIFFERENTIATION OF STEM CELLS INTO VASCULAR CELLS AND THE INDUCTION OF ANGIOGENESIS USING THE SAME

FIELD OF THE INVENTION

- 5 [001] The present invention relates to a method for differentiation of stem cells into vascular cells by culturing stem cells in the form of a three-dimensional cell cluster and the use of the three-dimensional cell cluster for *in vivo* angiogenesis.

BACKGROUND OF THE INVENTION

- 10 [002] Angiogenesis is the process of new blood vessel formation by degradation of extracellular matrix (ECM), migration, division, and differentiation by pre-existing vascular endothelial cells. Angiogenesis is involved in various physiological and pathological events, such as embryonic development, wound healing, tumor growth, chronic inflammation, obesity, etc. Angiogenesis includes the proliferation of
- 15 vascular endothelial cells and their migration from the blood vessel wall to the surrounding tissue following the source of the angiogenic stimuli. Sequentially, the activation of various proteases helps the vascular endothelial cells to degrade the basement membrane and form loops. These formed loops differentiate into new vessels.
- 20 [003] The angiogenic process is known to be strictly regulated by various types of angiogenic simulators and inhibitors. Angiogenesis does not occur in a normal state due to a quantitative balance between angiogenic inhibitors, such as thrombospondin-1, platelet factor-4, angiostatin, etc., and angiogenic stimulators, such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), etc.
- 25 However, when a wound or tumor occurs, for the wound healing or tumor growth, the

above balance is upset to enable new blood vessels to grow. The formation involves an overexpression of angiogenic stimulators.

[004] Angiogenesis is an essential step for tissue regeneration, as well as wound healing. For example, a placenta in which angiogenesis is underdeveloped is an important cause of miscarriage. Necrosis, ulcer, and ischemia caused by non-formation of vessels cause malfunction of tissues or organisms, or can lead to death. In addition, atherosclerosis, myocardial infarction, and angina pectoris are due to an inadequate blood supply. Accordingly, treatment methods of reducing tissue damage caused by hypoxia or undernutrition due to incomplete blood vessel formation, while inducing or stimulating neovascularization for proper tissue regeneration, are needed.

[005] A therapy of treating diseases using angiogenesis is called an angiogenic therapy. VEGF, an angiogenic simulator, is used as a therapeutic agent for severe local anemia. In addition, angiogenic simulators, such as FGF, epidermal growth factor (EGF) and platelet-derived endothelial growth factor (PDEGF), are also being studied for clinical treatment. However, the above factors are disadvantageous for clinical applications because they are proteins which are difficult and costly to isolate and purify.

[006] In 1997, Asahara and colleagues reported that a purified population of CD34⁺ hematopoietic progenitor cells isolated from the circulation system of adults could be *in vitro* differentiated into endothelial lineage cells named endothelial progenitor cells (EPCs). Based on the above, bone marrow-derived cells and EPCs proliferated *ex vivo* were used in the treatment of limb ischemia and the regeneration of heart muscles. The EPCs were tried in auto-transplantation for blood vessel regeneration. After that, it was reported that not only stromal vascular fraction (SVF) in the adipose tissue but mesenchymal stem cells (MSCs) found in bone marrow and umbilical cord blood could also be differentiated into vascular endothelial cells. Adipose stem cells could be

differentiated *ex vivo* into vascular endothelial cells and showed early angiogenesis activity in ischemia animal models.

[007] However, because stem cells are individually transplanted in animal models of ischemia using MSCs, most reports so far have said that growth factors secreted from the stem cells, rather than the stem cells themselves, induce angiogenesis of the host. Some stem cells are introduced into the newly formed blood vessels but there have been no reports that stem cells *per se* induce angiogenesis. There has also been a report that when cells produced by decomposing adipose tissues were transplanted into animals without culturing the stromal vascular fraction (SVF) therefrom, it was possible to differentiate them into vascular endothelial cells. However, since the above method did not induce proliferation of adipose stem cells via subculturing, the amount of vascular endothelial cells differentiated from the adipose stem cells was very small. In particular, since the differentiated vascular endothelial cell showed low levels of proliferation and differentiation, the application is limited.

[008] Therefore, the present inventors conducted extensive research on an angiogenic therapy using stem cells for effectively inducing angiogenesis of stem cells transplanted in the body. As a result, the present inventors found that, if stem cells are cultured on a culture plate with a surface of a hydrophobic property by physically attaching the cells to the culture plate via cell-matrix interactions, or they are cultured where they are bonded to growth factors immobilized to the surface of the culture plate via their interaction with the growth factors, stem cells proliferate while being attached to the surface of the culture plate initially, while the proliferated stem cells are later detached from the surface of the culture plate to form a three-dimensional cell cluster as the intercellular interaction becomes stronger than the cell-matrix interaction under high cellular density. The present inventors further discovered that the stem cells within the thus formed cell cluster not only secrete angiogenic stimulators, but are also

differentiated into vascular cells. Based on the above findings, the present inventors developed a method of using a cell cluster composed of vascular cells differentiated from stem cells as a cell therapy agent for angiogenesis to achieve the present invention.

5

SUMMARY OF THE INVENTION

[009] It is, therefore, an objective of the present invention to provide a method for differentiation of stem cells into vascular cells in high yields within a short period of time for the *in vivo* induction of angiogenesis using the stem cells, where the method comprises culturing stem cells in the form of a three-dimensional cell cluster.

10 **[010]** It is another objective of the present invention to provide a cell therapy agent for vascular diseases or functional cells in a composite scaffold for use in tissue engineering comprising a three-dimensional cell cluster, where the three-dimensional cell cluster is composed of vascular cells differentiated from stem cells by the above method.

15

TECHNICAL MEANS TO SOLVE PROBLEMS

In order to achieve the above objectives, the present invention provides a method for the differentiation of stem cells into vascular cells comprising culturing stem cells by
20 adhering them onto a culture plate with a surface having a hydrophobic property or a culture plate onto which a growth factor is immobilized, where the cultured stem cells are subsequently detached from the culture plate at a high cellular density to form a three-dimensional cell cluster and grown in the form of a three-dimensional cell cluster while differentiating into vascular cells.

25 **[011]** In addition, the present invention provides a cell therapy composition for the

treatment of vascular disease or wound healing having a three-dimensional cell cluster as an active ingredient, the three-dimensional cell cluster being composed of vascular cells differentiated from stem cells by the above method.

5 [012] Further, the present invention provides a tissue engineering composite scaffold for regeneration of blood vessels in which a three-dimensional cell cluster composed of vascular cells differentiated from stem cells by the above method is loaded on a biodegradable scaffold.

EFFECT OF THE INVENTION

10

[013] The differentiation method according to the present invention utilizes the physical interactions between stem cells and the hydrophobic surface of a culture plate or biochemical interactions between stem cells and growth factors immobilized on the same culture plate surface to culture the stem cells in the form of a three-dimensional
15 cell cluster. By doing so, hypoxia is created within the cell cluster, resulting in an overproduction of angiogenic stimulators. As a result, differentiation of the stem cells into vascular endothelial cells can be effectively induced. If the three-dimensional cell cluster obtained by the differentiation method of the present invention is transplanted into the body, mature blood vessels can be effectively formed *in vivo* by
20 the actions of the abundant angiogenic stimulators and vascular cells differentiated from the stem cells. Accordingly, the cell cluster according to the present invention is useful as a cell therapy agent for the treatment of vascular diseases or wound healing. In addition, the cell cluster according to the present invention can be useful as a composite scaffold for regeneration of blood vessels in combination with a
25 biodegradable scaffold.

BRIEF DESCRIPTION OF THE DRAWINGS

[014] Fig. 1a is a photograph showing multipotent adipose stem cells isolated from human subcutaneous adipose tissue, observed using a contrast-phase microscope under a magnification of 40.

5 [015] Fig. 1b shows the results of analyzing the expression profiles of surface antigens to multipotent adipose stem cells differentiated from human subcutaneous adipose tissues using flow cytometry.

[016] Fig. 2 is a graph showing the quantification of the adhesion activity of cells to various surfaces of culture plates by measuring the amounts of proteins adhered to the
10 culture plate surfaces.

[017] Fig. 3 is a photograph showing the formation of a three-dimensional cell cluster formed by culturing adipose stem cells in culture plates with various adherent activity to the cells, observed using a contrast-phase microscope under a magnification of 40.

[018] Fig. 4 shows the results from immunological staining of the three-dimensional
15 cell cluster formed from adipose stem cells according to the present invention for CD29, CD34, KDR, CD31, and SMA.

[019] Fig. 5 illustrates the results from immunological staining of the three-dimensional cell cluster formed from adipose stem cells according to the present invention for osteocalcin, nestin, MAP-2, and mouse IgG as a negative control.

20 [020] Fig. 6 is a photograph showing the three-dimensional cell cluster formed by culturing adipose stem cells in a FGF-immobilized culture plate according to the present invention, observed using a contrast-phase microscope under a magnification of 40.

[021] Fig. 7 shows the results from a RT-PCR analysis of HIF-1 α expression in the
25 three-dimensional cell cluster formed by culturing adipose stem cells in a FGF-

immobilized culture plate according to the present invention.

[022] Fig. 8 illustrates the results from examining the production of angiogenic stimulators within the three-dimensional cell cluster formed by culturing adipose stem cells in a FGF-immobilized culture plate according to the present invention.

5 [023] Fig. 9a shows the results from immunological staining of the cell cluster formed from culturing adipose stem cells in a medium with serum on a growth factor-immobilized culture plate according to the present invention for CD29, CD34, KDR, and CD31.

[024] Fig. 9b illustrates the results from immunological staining of the cell cluster
10 formed from culturing adipose stem cells in a medium with serum on a growth factor-immobilized culture plate according to the present invention for SMA, nestin, and MAP-2.

[025] Fig. 10 shows the results from immunological staining of the cell cluster formed from culturing adipose stem cells in a serum-free medium on a growth factor-immobilized culture plate according to the present invention to CD29, CD34, KDR,
15 and CD31.

[026] Fig. 11 is a schematic diagram showing *in vivo* transplantation of the three-dimensional cell cluster formed from culturing adipose stem cells according to the present invention in nude mice and the results from a naked eye observation of the
20 tissues removed from the mice three weeks after transplantation.

[027] Fig. 12 shows the results from immunological staining of the tissues of Fig. 11 for SMA, CD31, CD34, and KDR.

[028] Fig. 13 illustrates the results of immunological staining of the ischemic tissues in ischemic rat models transplanted with the cell cluster composed of vascular cells
25 differentiated from adipose stem cells according to the present invention for SMA, CD29 and CD31.

[029] Fig. 14 is a graph showing the quantification of blood flow in the hind limb of ischemic rat models transplanted with the cell cluster composed of vascular cells differentiated from adipose stem cells according to the present invention.

5

DETAILED DESCRIPTION OF THE INVENTION

[030] The present invention provides a method for the differentiation of stem cells into vascular cells by culturing stem cells in the form of a three dimensional cell cluster.

[031] The present invention is based on the discovery that the adherent activity of stem cells varies depending on the surface characteristics of a culture plate and the morphology of the cells to be finally obtained may differ according to the extent of the adhesion. According to the above finding, if stem cells are cultured on a culture plate with a surface of hydrophobic property, there is not a sufficiently strong adherent activity between the stem cells and the culture plate due to the hydrophobic surface, and the stem cells, at the early stage, proliferate while being attached to the surface of the culture plate due to cell-matrix interactions. However, with the passage of culture time, the stem cells, at high cell density, are detached from the surface and grow while floating in a culture medium and form a three-dimensional cell cluster through cellular interactions. In such a three-dimensional cell cluster, differentiation of the stem cells into vascular cells occurs.

[032] Cell adhesion onto a surface of biological materials occurs by various mechanisms and can be classified into specific cell adhesion mediated by biological recognition and non-specific adhesion governed by static electrical or surface energy. Specific cell adhesion occurs when specific peptide ligands present in ECM proteins (e.g., collagen, fibronectin, laminin, etc.), such as Arg-Gly-Asp (RGD), bind to integrins that are adhesion receptors present on the cell membrane. Non-specific cell

25

adhesion is a process by which the surface to be adhered by cells is made electropositive to induce the adhesion of the cells since cell membranes mainly composed of phospholipids are electrically negative. Most currently available tissue cell culture plates have surfaces which are made electropositive by plasma treatment
5 based on such non-specific cell adhesion principle. In addition to the method described above, cell adhesion can be induced if the surface to be adhered by cells is imparted with surface energy corresponding to that of the cell membrane.

[033] Adhesion-dependent cells such as epithelial cells or mesenchymal cells, which adhere to the extracellular matrix and grow, unlike blood cells, go into apoptosis, if
10 they do not adhere to the matrix. Such apoptosis is called *anokis*. The adhesion of cells to the matrix greatly affects the growth and differentiation of the cells.

[034] The *in vitro* cell culture of such adhesion-dependent cells involves intercellular interactions and cell-matrix interactions. Only when cell-matrix interactions are stronger than intercellular interactions can cells proliferate while forming a two-
15 dimensional monolayer on the surface of a culture plate. Meanwhile, at the early stage the cells cannot adhere to the surface of the culture plate because the intercellular interactions are stronger than the cell-matrix interactions, most cells are unable to proliferate, leading to death. Accordingly, in order to induce a three-dimensional culture of adhesion-dependent cells, it is important that at the early stage, the cells are
20 cultured while being attached to the surface of a culture plate and subsequently, where intercellular adhesion is induced at a high cell density, an environment where the cells can be detached from the culture plate and grow while floating and form a three-dimensional cell cluster needs to be created.

[035] Therefore, the present inventors invented a method of appropriately controlling
25 the force involving cell-matrix interactions rather than that involving cellular interactions, in order to induce cell culture in the form of a three-dimensional cell

cluster. More specifically, the present inventors developed a method of gently inducing cell adhesion such that at the early stage of culture, the cells proliferate while being individually adhered onto the surface of a culture plate but after passage of time, adhesion between cells is induced at a high cellular density, and the cells are detached
5 from the surface.

[036] In order to achieve the above, in the present invention, culture plates having various surface characteristics were screened for cell adherent activity of stem cells using adipose stem cells. As a result, in the culture plates coated with ECM proteins such as collagen, fibronectin, and laminin, and those imparted with an electropositive
10 property by plasma treatment on the surfaces, cell-matrix interactions were superior and thus the adipose stem cells proliferated while being adhered to the surface of the culture plates. On the other hand, the adhesion of the adipose stem cells was very weak in the culture plates adsorbed with bovine serum protein (BSA) used to impart hydrophilic properties and with a synthetic saccharide polymer having an amphipathic
15 property, i.e., poly-(*N-p*-vinylbenzyl-4-*O*- α -D-glucopyranosyl-D-gluconamide (PVMA), poly-(*N-p*-vinylbenzyl-4-*O*- β -D-galactopyranosyl-D-gluconamide (PVLA), and poly-(*N-p*-vinylbenzyl-1,2-D-glucuronamide (PV6Gna). However, it was surprisingly found that in culture plates having a polystyrene surface with a hydrophobic property, cell-matrix interactions were not sufficiently strong and thus at the early stage, the
20 adipose stem cells adhered and grew onto the surface of the culture plate, but after passage of a certain period of time, they were detached from the surface and grown while floating in a culture medium.

[037] Accordingly, the present inventors discovered that if stem cells are cultured in the form of a three-dimensional cell cluster by adjusting the culture time-dependent
25 adherent activity of stem cells by using a culture plate with a surface having a hydrophobic property, the stem cells can be differentiated into vascular cells.

[038] Based on the above finding, the differentiation method according to the present invention comprises culturing stem cells by adhering them onto a culture plate with a surface having a hydrophobic property (step 1), where the cultured stem cells are later detached from the culture plate as their density increases to form a three-dimensional cell cluster while growing in a floating state in the culture medium (step 2) and differentiate into vascular cells while growing in the form of the three-dimensional cell cluster (step 3).

[039] Step 1 involves culturing stem cells by attaching the stem cells onto a culture plate with a surface having a hydrophobic property. In this step, the stem cells are attached onto a culture plate via a physical interaction with the hydrophobic surface or via a biochemical interaction with a growth factor having adhesion activity to the stem cells that has been immobilized on the surface of the culture plate.

[040] Stem cells which can be used in step 1 include cells that remain undifferentiated while retaining the capability of being differentiated into all types of cells constructing the body, such as blood vessels, neurons, blood, cartilage, etc., in particular, multipotent adult stem cells that are activated only in tissues having the same characteristics as their original tissue. Examples of such stem cells may include adipose stem cells, mesenchymal stem cells, bone marrow stem cells, umbilical cord blood stem cells, neural stem cells, induced pluripotent stem cells, etc.

[041] In one embodiment of the present invention, multipotent stem cells derived from human adipose tissues derived are used. The multipotent stem cells are cultured by physically attaching the stem cells to a culture plate having a surface of a hydrophobicity property via cell-matrix interaction. Human adipose tissues suitable for the present invention are those composed of mature adipose cells and connective tissues surrounding the same and can be easily obtained from patients themselves or others having the same phenotype. Irrespective of where they are located in the body,

any adipose tissue obtained by any method for collecting fat can be used.

Representative adipose tissues include subcutaneous adipose tissue, bone marrow adipose tissue, mesentery adipose tissue, stomach adipose tissue, retroperitoneal adipose tissue, etc.

- 5 [042] Adipose stem cells can be isolated from human adipose tissues by using known methods. For example, as disclosed in PCT International Patent Publication Nos. WO 2000/53795 and WO 2005/04273, the adipose stem cells can be obtained by liposuction, precipitation, enzymatic treatment with collagenase, removal of drifting cells such as erythrocytes using a centrifuge, etc.
- 10 [043] In some embodiments of the present invention, human adipose tissue obtained as incidentals during liposuction are washed with a phosphate buffered saline (PBS) and then chopped. The chopped tissues are treated at 37°C for a time period of 1 to 6 hours using a serum-free medium in which collagenase type I is added. Subsequently, after the PBS wash, the supernatant is removed by centrifugal separation at a speed of
- 15 1000 rpm while the pellet is separated from the bottom. The separated pellet is washed with PBS and then subjected to centrifugation at a speed of 1000 rpm for 5 minutes. The above obtained supernatant is filtered while removing drifting cells such as erythrocytes and cell debris, and then washed with PBS. The supernatant is cultured in a medium with serum for 24 hours and then the cells that have not been
- 20 attached to the bottom of the culture plate are washed with PBS, where the serum-containing medium is replaced every two (2) days, and cultured to obtain multipotent adipose stem cells. The adipose stem cells isolated as above show a superior proliferation rate despite numerous passages, i.e., until the passage number reaches sixteen (16). Accordingly, as for the multipotent adipose stem cells isolated from
- 25 human adipose tissues according to the present invention, the primary culture may be used as is or the cells that have undergone at least ten subcultures under 60%

confluency may be used in the subsequent step of forming a three-dimensional cell cluster. If adipose stem cells that have been sufficiently proliferated by subculture are used, then differentiation into vascular endothelial cells can be induced in a high yield in a short period of time.

- 5 [044] When the adipose stem cells thus prepared are inoculated and cultured on a culture plate having a surface with a hydrophobic property, due to the hydrophobic surface, cell-matrix interactions occur between the adipose stem cells and the culture plate and the adipose stem cells proliferate while being attached to the surface of the culture plate via physical adsorption.
- 10 [045] Culture plates with a surface having a hydrophobic property suitable for the present invention are conventional cell culture plates having a surface which is treated with polymers that impart a hydrophobic property to the cell culture plates or cell culture plates made from such polymers. Such polymers may be, but not limited to, one selected from polystyrene, polymethylmethacrylate (PMMA), polyethylene
- 15 terephthalate (PET), polyvinylchloride (PVC), polyethylene (PE), polypropylene (PP), polytetrafluoroethylene (PTFE), aliphatic polyester based polymer selected from poly(L-lactic acid) (PLLA), poly(D,L-lactic acid) (PDLLA), poly(glycolic acid) (PGA), poly(caprolactone) (PLC), poly(hydroxyalkanoate), and polydioxanone (PDS), polytrimethylencarbonate, copolymers thereof such as poly(lactic acid-co-glycolic
- 20 acid) (PLGA), poly(L-lactic acid-co-caprolactone) (PLCL), poly(glycolic acid-co-caprolactone) (PGCL), derivatives thereof, etc. In addition, culture plates suitable for the present invention may have a silanized surface, carbon nano tube surface, hydrocarbon coated surface and metallic (e.g., stainless steel, titanium, gold, platinum, etc.) surface as the surface with a hydrophobic property.
- 25 [046] In another embodiment of the present invention, in order to adhere stem cells onto a culture plate more effectively than physical adsorption by interactions between

the stem cells and the hydrophobic culture plate, biochemical interactions between the stem cells and growth factors having adherent activity to the stem cells that are immobilized onto the surface of the culture plate may be used.

[047] As growth factors suitable for the present invention, any growth factor having an adherent activity to stem cells can be used, for example vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), epidermal growth factor (EGF), platelet-derived endothelial growth factor (PDGF), hepatocyte growth factor (HGF), insulin-like growth factor (IGF) and heparin binding domain (HBD). These growth factors can be immobilized on the surface of a culture plate at a concentration between 5 and 100 µg/ml. In some embodiments of the invention, FGF as a growth factor having adherent activity to stem cells is immobilized on the hydrophobic surface of a culture plate. FGF (NCBI GenBank Accession No. EF506888.1) is a growth factor which binds to a FGF receptor or HSPG present on the membrane of stem cells to exhibit biological functions important for differentiation or proliferation when culturing adipose stem cells, mesenchymal stem cells, embryonic stem cells, etc.

[048] Immobilization of a growth factor on the surface of a culture plate uses the same method as immobilization of a polypeptide on a solid substrate surface, which can be achieved by any known method in the art. Conventionally, physical adsorption, covalent binding via non-selective chemical reactions, etc., can be used. In such immobilization methods, the following known methods may be used: a method of immobilizing proteins by means of biotin-streptavidin/avidin interaction by biotinyllating the proteins and applying the biotinyllated proteins onto a solid surface treated with streptavidin or avidin; a method of immobilizing proteins by integrating active moieties (chemical functional groups for immobilizing proteins by chemical binding) on a substrate using plasma; a method of immobilizing proteins on a solid substrate surface, on which a porous sol-gel thin film having a sufficiently increased

specific surface area is formed via a sol-gel method, by physical adsorption to the porous sol-gel thin film; a method of immobilizing anti-thrombotic proteins on polytetrafluoroethylene (PTFE) surfaces by using a plasma reaction; a method of immobilizing proteins by binding enzymes in which at least two cationic amino
5 residues are successively fused to two enzymes; a method of immobilizing proteins on a hydrophobic polymer layer bound to a solid phase support using a matrix; a method of immobilizing proteins on a plastic surface using a buffering component; and a method of immobilizing proteins by contacting said proteins with a solid surface having a hydrophobic property in an alcohol solution.

10 **[049]** In one embodiment of the present invention, a polypeptide linker that is capable of being expressed in a large amount and is easy to purify is used. The immobilization is carried out in the form of a recombinant protein having a polypeptide linker and a growth factor in which the amino terminal group of the growth factor is fused to the carboxyl terminal group of the polypeptide linker. In the present
15 invention, a growth factor essential for the differentiation and proliferation of stem cells is immobilized on the hydrophobic surface in the form of a recombinant protein with a polypeptide linker while retaining the original biological activity of the growth factor. The immobilized growth factor's adhesion activity to stem cells enables the stem cells to be adhered onto the surface and promotes effective culture of the stem cells.

20 **[050]** As a polypeptide linker suitable for the invention, any linker may be used as long as its carboxyl terminal group can be linked to an amino terminal group of a growth factor and its amino terminal hydrophobic domain allows for adhesion onto a culture plate with a hydrophobic surface. Any linker that can be mass produced and easily purified in the form of a recombinant protein without affecting the stem cell
25 culture may be used. Such polypeptide linkers may be maltose-binding protein (MBP), hydrophobin, hydrophobic cell penetrating peptides (CPPs), etc.

[051] In some embodiment of the invention, a growth factor is immobilized onto a surface of a culture plate using maltose-binding protein (MBP) as a polypeptide linker. MBP (NCBI GenBank Accession No. AAB59056), which is located in the periplasm across the cell membrane of *Escherichia coli*, is a periplasm protein involved in the migration of saccharides such as maltose or maltodextrin.

[052] MBP, which is mainly used for the production of useful exogeneous proteins into recombinant proteins, is produced from *malE* gene in the cell. When genes encoding an exogeneous protein are inserted into downstream of the cloned *malE* gene and expressed in the cell, a recombinant protein in which two proteins are combined can be easily produced in high yields. In particular, where exogeneous proteins to be expressed are small or less stable in other host cells, it is advantageous to express them in a recombinant protein form using MBP as above. The exogeneous proteins expressed from *malE*-fused genes can be isolated using MBP's binding affinity to maltose. For example, a resin coated with amylose, which is a poly-maltose, is reacted with a cell homogenate. The reacted resin is washed several times to remove other contaminated proteins and then a high concentration of maltose is added to the resin to compete, where only the desired protein can be eluted.

[053] Therefore, the present invention provides a recombinant protein using a MBP that is expressed in *E. coli*. and is easy to express and purify due to its superior binding ability to maltose, in which a carboxyl terminal group of maltose is linked to an amino terminal group of FGF. This recombinant protein is immobilized onto a culture plate with a surface having a hydrophobic property by simple physical adsorption using a hydrophobic domain of MBP as a linker. Subsequently, stem cells are attached to the surface of the culture plate through adhesion between the FGF portion which still maintains the biological activity in the immobilized recombinant protein and the stem cells. While the carboxyl terminal group in MBP is used in binding to FGF for

preparing the recombinant protein, the amino terminal group containing a hydrophobic domain is used in physical adsorption to the hydrophobic surface in the subsequent steps.

5 [054] The MBP-FGF recombinant protein retaining the adherent activity to stem cells provided as above where the carboxyl terminal group of the maltose binding protein (MBP) is fused to the amino terminal group of the fibroblast growth factor (FGF) may have an amino acid sequence of **SEQ ID NO: 1**.

10 [055] The MBP-FGF recombinant protein can be prepared using conventional chemical synthesis or genetic recombination technology, or obtained by recovering the recombinant protein after culturing transformed bacteria expressing the recombinant protein under suitable conditions. Such transformed bacteria include *E. coli* transformant K12 TB1 (pMAL-bFGF) which was deposited in the Gene Bank in Korea Research Institute of Bioscience & Biotechnology under Deposit No. KCTC-11505BP on April 28, 2009.

15 [056] The MBP-FGF recombinant protein thus obtained is immobilized onto a culture plate having a hydrophobic surface without requiring any special treatment. That is, the recombinant protein is spontaneously immobilized via physical adsorption of the hydrophobic domain positioned in the amino terminal group of a polypeptide linker of the same recombinant protein to the hydrophobic surface.

20 [057] In some embodiments of the present invention, the MBP-FGF recombinant protein is diluted to 1 ng/ml to 0.5 mg/ml in a suitable buffer, e.g., phosphate buffered saline (PBS), Twin 20/PBS, Tris-HCl buffer, bicarbonate buffer, etc. The diluted solution is added to a culture plate with a hydrophobic surface and reacted at 4-25°C for 1-24 hours and then the recombinant protein is immobilized onto the hydrophobic
25 surface via physical adsorption of a hydrophobic domain located in the amino terminal group of MBP to the hydrophobic surface. The MBP-FGF recombinant protein to be

immobilized on the hydrophobic surface may have a concentration of from 5 to 100 $\mu\text{g/ml}$.

[058] In the recombinant protein immobilized onto a hydrophobic surface of a culture plate as above, because FGF which is important for cell recognition is exposed on the outside, it can easily bind to FGF receptors or HSPG present on the membrane of stem cells and thus play a key role in regulating cellular functions. Accordingly, if stem cells are cultured on a FGF-immobilized culture plate, they can then be cultured while being attached onto the culture plate via direct interactions between the stem cells and FGF.

[059] As described above, if in step 1, stem cells are cultured by physically attaching them to a culture plate having a surface with a hydrophobic property via cell-matrix interactions or they are cultured while being bonded to a growth factor immobilized on a surface of the culture plate via biochemical interactions with the growth factor, the stem cells proliferate while being attached to the surface of the culture plate at an early stage.

[060] In step 2, the stem cells that proliferate while being attached to the surface of the culture plate in step 1 are detached from the surface of the culture plate at a high cell density where intercellular interactions are stronger than cell-matrix interactions. The detached stem cells grow while floating in a culture medium and aggregate to one another to form a floating three-dimensional cell cluster of a millimeter size that is visibly detectable.

[061] In certain embodiments, a non tissue culture plate (NTCP) made of polystyrene is used as a culture plate having a surface with a hydrophobic property and inducing relatively weak cell adhesion to the plate surface. In the culture plate, human adipose stem cells are inoculated to induce formation of a three-dimensional cell cluster. In the early stage, the adipose stem cells inoculated to the polystyrene NTCP proliferate in

a second-dimensional monolayer while being adhered to the surface of the culture plate due to the weak cell adhesion induced by cell-matrix interactions. As the density of the cells increases according to the passage of culture time, intercellular interactions become stronger than cell-matrix interactions and the cells cultured in a second-
5 dimensional monolayer are detached from the surface of the culture plate. In this regard, it is important to culture the adipose stem cells while they are attached to the surface of the culture plate in the early stage. If the stem cells are cultured in a floating state without being attached to the surface in the early stage, the size of the formed three-dimensional cell cluster is small and most of the cells perish. If the cells
10 detached from the culture plate are further cultured in a floating state in a culture medium, they aggregate to one another via intercellular interactions to form a three-dimensional cell cluster. In the three-dimensional cell cluster thus formed, cells are weakly combined to each other in the early stage. With the passing of culture time, the adhesion between cells is strengthened by intercellular interactions to form a
15 compact three-dimensional cell cluster.

[062] The three-dimensional cell cluster formed according to the present invention has a visually detectable size, specifically having a diameter of from 400 μm to 1 mm. In the present invention, the size of the three-dimensional cell cluster is very important for the differentiation of stem cells into vascular endothelial cells. This is because the
20 larger the cell cluster is, the smaller the amount of oxygen transmitted into the cell cluster. This creates hypoxia inside the cell cluster by which the production of various angiogenic stimulators affecting the differentiation of vascular endothelial cells is induced. Accordingly, when the diameter of a three-dimensional cell cluster is less than 400 μm , stem cells may not be effectively differentiated into vascular endothelial
25 cells. On the other hand, when the diameter is greater than 1 mm, apoptosis may be induced due to excessive oxygen deficiency inside the cell cluster.

[063] In general, if hypoxia is created by artificially restricting the oxygen supply to monolayer-cultured cells, angiogenic stimulators such as VEGF may be produced.

However, since the angiogenic stimulators thus formed are likely to be diffused into the excessive amount of medium, the chance that the cells will actually absorb the

5 angiogenic stimulators is slim. On the other hand, if a cell cluster is formed as in the present invention, the angiogenic stimulators produced inside the cell cluster can directly act on the cells. Accordingly, the stem cells can grow in the presence of a high concentration of angiogenic stimulators, and thus, can be effectively differentiated into vascular endothelial cells.

10 [064] In order to form a three dimensional cell cluster having a size of the above mentioned range, it is desirable that in step 2, stem cells are inoculated at a concentration of from 1×10^4 to 3×10^5 cells/cm². In the case where the concentration of the inoculated stem cells is less than 1×10^4 cells/cm², the size of the cell cluster cannot be reproduced, while when the concentration is greater than 3×10^5 cells/cm²,
15 apoptosis may occur due to inoculation of an excessive number of cells.

[065] In some embodiments of the present invention, in order to induce the formation of a three-dimensional cell cluster of adipose stem cells, the isolated adipose stem cells are suspended in a serum medium and then inoculated to each well of polystyrene well plates at a concentration of from 1×10^4 to 3×10^5 cells/cm². As a result, three days
20 after culturing at a concentration of at least 2×10^4 cells/cm², it is confirmed that a three-dimensional cell cluster having a diameter in the range of from 500 μ m to 1 mm is induced. The size of the formed three-dimensional cell cluster varies depending on the initial concentration of the inoculated adipose stem cells. Specifically, inoculation of adipose stem cells at a concentration of at least 4×10^4 cell/cm² is convenient to form
25 and recover a visibly detectable size of a three-dimensional cell cluster.

[066] In Step 3, stem cells grow in the form of the three-dimensional cell cluster

formed in Step 2 while being differentiated into vascular endothelial cells. If the stem cells are cultured in the form of a three-dimensional cell cluster, oxygen transmission to the inside of the cell cluster decreases, thereby creating hypoxia. The hypoxia created inside the cell cluster induces the production of various angiogenic stimulators
5 affecting the vascular endothelial cell differentiation, finally leading to the differentiation of the stem cells into vascular endothelial cells.

[067] In Step 1, in the case where the stem cells are cultured by attaching to a culture plate having a surface of a hydrophobic property, it is preferred to culture the stem cells inoculated to the culture plate at a temperature between 35°C and 38.5°C for 1 to 7 days
10 so that a three-dimensional cell cluster composed of vascular endothelial cells differentiated from the stem cells can be obtained.

[068] Alternatively, in Step 1, in the case where the stem cells are cultured by attaching them to a culture plate on which a growth factor having adherent activity to the stem cells is immobilized, it is desirable to culture the stem cells inoculated to the
15 culture plate at a temperature between 35°C and 38.5°C for 1 to 7 days so that a three-dimensional cell cluster composed of vascular endothelial cells differentiated from the stem cells can be obtained.

[069] As for a suitable medium for the above culture, any medium, with or without serum, conventionally used in the culture and/or differentiation of stem cells can be
20 used without limitation, for example Dulbecco's modified eagle medium (DMEM), Ham's F12, and medium in which a serum is added to a mixture thereof. In certain embodiments of the invention, a medium in which a fetal bovine serum (FBS) is added to DMEM/F12 medium where DMEM and Ham's F12 are mixed in a volume ratio of 1:1 is used.

[070] Since the three-dimensional cell cluster formed by culturing stem cells by
25 attaching them to the surface of a culture plate as above has a visibly detectable size,

specifically a diameter ranging from 400 μm to 1 mm, it can be easily recovered through filtration or centrifugation. The three-dimensional cell cluster thus recovered is degraded by enzymatic treatment using collagenase, trypsin or dispase, mechanical treatment using pressure, or a combined treatment of the foregoing and is used in
5 unicellular forms or can be used in a three-dimensional cell cluster form as is.

[071] The three-dimensional cell cluster formed according to the present invention may be analyzed using immunological staining. The three-dimensional cell cluster shows an immunological phenotype specific to the vascular endothelial cells, by which it can be confirmed that the adipose stem cells differentiated into vascular endothelial
10 cells. Specifically, the three-dimensional cell cluster formed according to the present invention exhibited a positive reaction with respect to CD29, which is a surface antigen expressed on mesenchymal stem cells and epithelial cells, CD34, KDR(kinase insert domain receptor; vascular endothelial growth factor receptor 2), and CD31(endothelial cell adhesion molecule, PECAM), which are surface antigens expressed on vascular
15 endothelial cells, and smooth muscle actin (SMA) and myosin heavy chain (MHC) which is expressed in smooth muscles. On the other hand, the three-dimensional cell cluster formed according to the present invention exhibited a negative reaction with respect to osteocalcin, nestin, and MAP-2, which are surface antigens expressed in bone cells and neural cells.

20 **[072]** Based on the above results, it can be confirmed that the stem cells are differentiated into vascular cells because the cells obtained by culturing stem cells in a three-dimensional cell cluster form according to the present invention are found to express surface antigens specific to vascular cells.

[073] As described above, the method of differentiating stem cells into vascular
25 endothelial cells according to the present invention can effectively differentiate stem cells into vascular endothelial cells by a three-dimensional cell cluster which is formed

by adjusting the adherent activity of stem cells to a culture plate by using a culture plate having a surface with a hydrophobic property or a growth factor immobilized onto the culture plate surface. In addition, if the three-dimensional cell cluster obtained according to the present differentiation method is transplanted *in vivo*, mature blood vessels can be effectively formed in the body by abundant angiogenic stimulators and vascular cells differentiated from the stem cells. Accordingly, the cell cluster according to the present invention can be used not only as a cell therapy agent for vascular diseases or wound healing, but also as a composite scaffold for use in tissue engineering for the regeneration of blood vessels along with a biodegradable scaffold.

10 [074] Therefore, the present invention provides a cell therapy composition useful for treating vascular diseases or would healing, the composition containing as an effective ingredient a cell cluster composed of the vascular cells differentiated from stem cells by the method described above.

[075] The vascular diseases in the present invention include cardiovascular disease, cerebrovascular disease, and ischemia disease, such as, for example, atherosclerosis, 15 stable and unstable angina pectoris, peripheral cardiovascular disease, hypertension, heart failure, peripheral circulatory disturbance, myocardial infarction, stroke, transient and ischemic attack, subarachnoid hemorrhage, etc.

[076] The cell therapy composition according to the present invention can be 20 administered in an amount of 1.0×10^7 to 1.0×10^8 cell/kg (body weight), more specifically 1.0×10^5 to 1.0×10^8 cell/kg (body weight), based on the vascular endothelial cells differentiated from stem cells which constitute the cell cluster as an active ingredient of the composition. However, the dosing amount can be prescribed depending on the formulation methods, administration methods, age, weight, sex, the 25 severity of disease, food, administration time, administration route, excretion rate, and response sensitivity. A person skilled in the art could appropriately adjust the dosing

amount in consideration of such factors. The composition can be administered once a day or at least twice a day to the extent that adverse effects are clinically acceptable.

In addition, it can be administered to one site or two or more sites. Further, the composition can be administered to non-human animals at the same amount per

5 kilogram. Otherwise, the composition can be administered in an amount obtained from converting the above dosing amount based on, for example, the volume ratio (e.g., mean value) of the ischemic organ (e.g., heart) of the subject animal and human. The subject animals to be treated by the present invention include humans and other mammals, specifically human, monkeys, rats, mice, rabbits, sheep, cows, dogs, horses,
10 pigs, etc.

[077] The cell therapy composition according to the present invention may comprise a cell cluster, as an active ingredient, and a pharmaceutically acceptable carrier and/or additives. For example, sterilized water, physiological saline, conventional buffers (phosphoric acid, citric acid, other organic acids, etc.), stabilizers, salts, anti-oxidants
15 (ascorbic acid, etc.), surfactants, suspensions, isotonic agents, preservatives may be included. For topical administration, it may be desirable to combine the present composition with organic compounds such as biopolymers, and inorganic compounds such as hydroxyapatite, specifically collagen matrix, polylactic acid polymer or copolymer, polyethyleneglycol polymer or copolymer and chemical derivatives thereof,
20 etc. In the case where the cell therapy composition according to the present invention is formulated into a dosage form suitable for injection, it is desirable that a cell cluster is dissolved in a pharmaceutically acceptable carrier or frozen as a solution.

[078] The cell therapy composition according to the present invention can appropriately include suspensions, dissolution aids, stabilizers, isotonic agents,
25 preservatives, anti-adhesion agents, surfactants, diluents, excipients, pH adjusting agents, pain relieving agents, buffers, sulphur-containing reducing agents, anti-oxidants,

etc., depending on its administration method or dosage form as necessary.

Pharmaceutically acceptable carriers and preparations suitable for the present invention including those mentioned above are described in detail in Remington's Pharmaceutical Sciences, 19th ed., 1995.

5 [079] The cell therapy composition according to the present invention can be formulated by using pharmaceutically acceptable carriers and/or excipients according to methods which can be easily carried out by those skilled in the art so that the composition can be manufactured as a unit dosage form or incorporated into a multiple dose container. The dosage forms may be a solution, suspension, or emulsion in oil or
10 aqueous medium, or powders, granules, tablets, or capsules.

[080] The cell therapy composition of the present invention comprising the cell cluster composed of the vascular cells differentiated from stem cells as described above is very useful for treating wounds, cardiovascular diseases, cerebrovascular diseases, ischemic diseases, etc.

15 [081] The present invention also provides a composite scaffold for use in tissue engineering for blood vessel regeneration containing the cell cluster composed of the vascular cells differentiated from stem cells as an active ingredient.

[082] The tissue engineering composite scaffold according to the present invention is characterized in that the cell cluster composed of the vascular cells differentiated from
20 stem cells is loaded in a scaffold made by molding a biodegradable polymer.

[083] The biodegradable polymer, which spontaneously and slowly decomposes in the body after a certain period of time, refers to a polymer possessing at least one characteristic from biocompatibility, blood-compatibility, anti-calc sintering property, and the capability of forming nutritional components and intercellular matrix. Such
25 biodegradable polymers include, but are not limited to, fibrin, collagen, gelatin, chitosan, alginate, hyaluronic acid, dextran, polylactic acid, poly(glycolic acid (PGA),

poly(lactic acid-co-glycolic acid), poly(lactic acid-co-glycolic acid (PLGA), poly-ε-(caprolactone), polyanhydride, polyorthoester, polyvinylalcohol, polyethyleneglycol, polyurethane, polyacrylic acid, poly-N-isopropylacrylamide, poly(ethyleneoxide)-poly(propyleneoxide)-poly(ethyleneoxide) copolymers, copolymers, and mixtures
5 thereof.

[084] In the tissue engineering composite scaffold, a biodegradable polymer may be specifically present in an amount from 5 to 99% by weight. If the amount of the biodegradable polymer is less than the above range, the composite scaffold does not form well, resulting in a scaffold with lower mechanical strength. On the other hand,
10 if the amount of the biodegradable polymer is greater than the above range, it is difficult to load the cell cluster.

[085] The composite scaffold can be manufactured by molding a biodegradable polymer using known methods, for example solvent-casting and particle-leaching technique, gas forming technique, fiber extrusion and fabric forming process, thermally
15 induced phase separation technique, emulsion freeze drying method, high pressure gas expansion, etc.

[086] The composite scaffold manufactured as described above plays a role in transferring the loaded cell cluster into transplanted tissues, enabling the cells to be attached to the composite scaffold and grow in a three-dimensional manner and the new
20 tissue to be formed. In order for the cells to be adhered to the composite scaffold and grow, the size and structure of the void of the scaffold matter. In order for a nutrition solution to evenly permeate into the interior of the scaffold so that the cells can grow well, it is desirable that the scaffold has interconnecting void structures. In addition, it is desirable that the composite scaffold according to the present invention has voids
25 with an average diameter of 50-600 μm.

[087] In the tissue engineering composite scaffold according to the present invention,

it is desirable that the vascular endothelial cells are loaded in the composite scaffold at a concentration of 2×10^4 to 3×10^5 cell/cm² based on the vascular endothelial cells differentiated from stem cells which constitute a cell cluster as an active ingredient of the composite scaffold. If the concentration of the vascular endothelial cells is less
5 than the above range, the effect of stimulating the vascular generation of vascular endothelial cells may be minimal. On the other hand, if the concentration is greater than the above range, there may be problems where the inoculated cells may perish due to nutrient and oxygen deficiencies.

[088] The cell cluster inoculated in a composite scaffold as described above enables
10 the vascular endothelial cells comprising the cell cluster to be differentiated into vascular cells, thereby effectively inducing the regeneration of vascular tissues in the organism into which the tissue engineering composite scaffold according to the present invention is transplanted.

[089] Hereinafter, the present invention will be described in more detail with
15 reference to the examples. However, it will be apparent to those skilled in the art that the following examples are for illustrative purposes only and that the invention is not intended to be limited by these examples.

EXAMPLES

20 **Reference Example 1: Isolation of multipotent stem cells from human adipose tissue**

[090] Subcutaneous adipose tissues of a normal person were supplied from the plastic surgery laboratory of Catholic University. The sample tissues were washed with a PBS solution containing 2% penicillin/streptomycin three times and contaminated
25 blood was removed. Thereafter, the blood-removed tissues were chopped using

surgical scissors. These chopped tissues were added in a tissue lysing solution (serum free DMEM + 1% BSA (w/v) + 0.3% collagenase type 1) which was prepared in advance and the solution was stirred at 37°C for 2 hours, followed by centrifugation at a speed of 1,000 rpm for 5 minutes to separate the supernatant and pellets. The supernatant was discarded and the pellets remaining at the bottom were harvested. The harvested pellets were washed with PBS and then centrifuged at a rate of 1,000 rpm for 5 minutes to collect the supernatant. The collected supernatant was filtered with a 100 µm mesh to remove the tissue debris and was then washed with PBS. The thus isolated cells were cultured in a DMEM/F12 medium (Welgene) containing 10% FBS. After culturing for 24 hours, the non-adherent cells were washed with PBS and removed. The isolated cells were cultured while replacing the DMEM/F12 medium containing 10% FBS every two (2) days, and then human subcutaneous adipose tissue derived stem cells were obtained.

[091] Fig. 1a is a photograph showing multipotent stem cells isolated from human subcutaneous adipose tissue observed using a contrast-phase microscope (Nikon) under a magnification of 100. Fig. 1b shows the results from a flow cytometry analysis of the cell surface antigen expression profiles of the above multipotent stem cells. As surface antigens for confirming the presence of mesenchymal cells, CD29, CD90, and CD105 were used. The separation of stem cells and incorporation of other cells during culture were examined using CD34 and HLA-DR as surface antigens. Based on the above results, it was confirmed that the cells separated from human subcutaneous adipose tissue were adipose stem cells having a phenotype of mesenchymal stem cells.

Example 1: Adherent activities of adipose stem cells with respect to various culture plate surfaces

[092] 20 µg/ml of various extracellular matrix proteins (i.e., collagen type 1, collagen type 4, fibronectin (FN), and laminine) and 100 µg/ml of saccharide polymer (i.e., poly-(*N*-p-vinylbenzyl-4-*O*-α-D-glucopyranosyl)-D-gluconamide), and 100 µg/ml of BSA were added in a 96-well plate for non-tissue cell culture (Non-Tissue Culture Treated 5 96-well Plate, "NTCP" made of polystyrene materials and having a surface with a hydrophobic property; Falcon). The well plate was stored at 25°C for 4 hours so as to be coated, and then washed with PBS three times. 100 µg/ml BSA was added to the well plate to carry out blocking at 25°C for 1 hour, followed by re-washing with PBS.

[093] The adipose stem cells prepared in Reference Example 1 were suspended in a 10 DMEM/F12 medium containing 10% FBS. The suspension was inoculated onto NTCP, a 96-well plate for tissue cell culture (Tissue Culture Treated 96-well Plate, "TCP," Falcon), and a well plate that is a NTCP coated with ECM proteins, saccharide polymers, and BSA at a concentration of 1.3×10^4 cell/cm² per well and the inoculated well plates were cultured in an incubator at 37°C. The degree of cell adhesion to the 15 plates and their adhesion morphologies were observed at 0.25, 0.5, 1. 2, and 4 hours after inoculation. Subsequently, the cells adhered to the surface of the plates at each time point were dissolved in a cell lysis buffer and then quantified using a bicinchoninic acid (BCA) protein assay.

[094] As a result, as shown in Fig. 2, no cell adhesion was observed in BSA- and 20 saccharide polymer-coated NTCPs, irrespective of the culture time. However, in TCP- and fibronectin-coated NTCP, high cell adhesion rates were exhibited starting from one hour after cell inoculation. In NTCP, the cell adhesion rate was not high two hours after cell inoculation, but at four hours after cell inoculation, a rapid increase in the cell adhesion rate was observed. Based on the above, it was confirmed that in 25 the plates coated with BSA and saccharide polymers, adipose stem cells had the lowest adherent activity while in TCP and plates coated with ECM proteins such as fibronectin,

they had the highest adherent activity. In NTCP having a surface with a hydrophobic property, such as polystyrene, it was confirmed that the adherent activity of adipose stem cells was weakly induced.

5 **Example 2: Formation of a three-dimensional cell cluster of adipose stem cells**

[095] In order to examine the correlation between the adherent activity of adipose stem cells with respect to culture plate surface and the formation of a three-dimensional cell cluster, as in Example 1 above, adipose stem cells were inoculated on a 96-well plate for non-tissue cell culture (NTCP, polystyrene), NTCPs coated with ECM
10 proteins (i.e., collagen and fibronectin), saccharide polymer (PVMA), and BSA, respectively, and a 96-well plate for tissue cell culture (TCP) at a concentration of 4×10^4 cell/cm² per well, followed by culturing in a DMEM/F12 medium containing 10% FBS for three (3) days. After the three day culture, whether or not a three-dimensional cell cluster of the adipose stem cells was formed on the surface of each
15 culture plate was observed.

[096] As shown in **Fig. 3**, in NTCP where cell adhesion was weakly induced due to the hydrophobic surface, a visibly detectable size of a three-dimensional cell cluster was observed. The three-dimensional cell cluster had a diameter of at least about 500 μm . On the other hand, in fibronectin-coated NTCP or TCP where cell adhesion
20 was strongly induced, the adipose stem cells were cultured in a monolayer while being adhered to the surface of the plates in a planar manner and thus no cell cluster was formed. In NTCP coated with BSA and PVMA in which cell adhesion hardly occurs, cell clusters with sizes not greater than 100 μm were sporadically formed but their size was too small. Based on the above results, it was confirmed that the formation of a
25 three-dimensional cell cluster of adipose stem cells is influenced by the adherent activity of the stem cells with respect to the surface of the culture plates used. It was

further confirmed that in order to form a three-dimensional cell cluster having a visibly detectable size, it is desirable to use a culture plate having a surface with a hydrophobic property such as NTCP made of polystyrene materials in which at an early stage, cell adhesion is less induced but as the density of cells increase according to the passage of
5 time, the cells are detached from the plate and grow while floating.

[097] In order to investigate the effective concentration required for forming a three-dimensional cell cluster that is visibly detectable in NTCP, the adipose stem cells obtained in Reference Example 1 were inoculated on 24-well and 6-well NTCPs which both contain a DMEM/F12 medium containing 10% FBS at a concentration of 0.5 x
10 10^4 to 1×10^5 cells/cm², followed by culturing the same for three (3) days. As a result, it was confirmed that the formation of a three-dimensional cell cluster having a visibly detectable size is efficiently induced at a concentration of at least 2×10^4 cells/cm².

Example 3: Immunological analysis of the three-dimensional cell clusters

15 [098] As in Example 2 above, adipose stem cells were inoculated in a 6-well NTCP at a concentration of 4×10^4 cells/cm² and cultured to form a three-dimensional cell cluster. The three-dimensional cell cluster was harvested and fixed at -70°C using an OCT compound and then cut to a thickness of 4 μm using a microtome. The fragment was fixed on a glass slide and immunologically stained. Alternatively, the harvested
20 three-dimensional cell cluster was physically broken up using a syringe, and then placed and adhered to a glass slide for 4 hours. Subsequently, the glass slide was washed with PBS several times, fixed by immersing in a 4% paraformaldehyde solution at room temperature for 30 minutes, re-washed with PBS, and immunologically stained. The immunological staining was carried out by soaking the glass slide prepared above
25 in PBS with a primary antibody to react overnight, followed by washing with PBS three times, and reacting with a secondary antibody in a dark room for one hour. After

termination of the reaction, the glass slide was washed with PBS three times, mounted and observed under a fluorescent microscope.

[099] As a result, the three-dimensional cell cluster formed from adipose stem cells according to the present invention exhibited a positive reaction with respect to CD29, CD34, KDR, CD31, and SMA, while exhibiting a negative reaction with respect to osteocalcin, nestin, and MAP-2. CD29 is a surface antigen which is specifically expressed on mesenchymal cells and epithelial cells, while CD34, KDR and CD31 are surface antigens specifically expressed on vascular endothelial cells. SMA is a cytoskeletal protein which is specifically expressed in smooth muscle cells. In addition, osteocalcin, nestin, and MAP-2 are proteins that are specifically expressed by bone cells and neural cells. Based on the above results, it was confirmed that a three-dimensional cell cluster formed by culturing adipose stem cells on a culture plate having a surface with a hydrophobic property are composed of vascular cells differentiated from the adipose stem cells.

[0100] Fig. 4 shows the results from immunological staining of the three-dimensional cell cluster formed from adipose stem cells as described above with respect to CD29, KDR, CD31, and SMA. Fig. 5 shows the results from immunological staining of the same three-dimensional cell cluster with respect to osteocalcin, nestin, MAP-2, and mouse IgG as a negative control.

20

Example 4: Immobilization of a growth factor on a hydrophobic surface

[0101] In order to more effectively induce stem cell culture in the form of a cell cluster, growth factors having adherent activity to the stem cells were immobilized onto a culture plate having a hydrophobic surface. As the growth factor, fibroblast growth factor (FGF) that is expressed in the form of a recombinant protein with a maltose binding protein (MBP) as a polypeptide linker was used.

25

[0102] Specifically, a MBP-FGF recombinant protein having adherent activity to stem cells, where the amino terminal group of FGF is fused to the carboxyl terminal group of MBP, was expressed from an *Escherichia coli* transformant, i.e., K12 TB1 (pMAL-bFGF) (KCTC-11505BP), and then isolated and purified. The thus obtained MBP-FGF recombinant protein has an amino acid sequence of **SEQ ID NO: 1**. The MBP-FGF recombinant protein can be used in biochemical interactions with stem cells because the original FGF activity is maintained even though it is expressed as a recombinant protein with MBP and purified.

[0103] The MBP-FGF recombinant protein purified as above was filtered using a syringe (0.22 μm , Millex GV, Millipore) in a clean bench (Sanyo), then added in each well of a 24-well plate for non-tissue cell culture (NTCP, polystyrene, Falcon) in the amount of 100 μl at a concentration of 10 $\mu\text{g}/\text{ml}$, and left in the clean bench for 4 hours so as to be immobilized on the surface of the plate. Subsequently, the 24-well plate was washed with 200 μl PBS three times and some of the wells were further treated by adding 1% bovine serum albumin (BSA, Sigma) in the clean bench for two (2) hours in order to prevent the stem cells from binding to the MBP-FGF recombinant protein-immobilized well surface in a non-specific manner. Subsequently, the 24-well plate was washed with 200 μl PBS three times to prepare a 24-well plate on which the MBP-FGF recombinant protein was immobilized.

20

Example 5: Formation of a cell cluster on the growth factor-immobilized surface

[0104] The adipose stem cells prepared in Reference Example 1 were inoculated at 4×10^4 cells/cm² per well of a 24-well plate of which the MBP-FGF recombinant proteins prepared in Example 4 were immobilized on the surface. The adipose stem cells were cultured in a medium containing 10% FBS or serum-free DMEM/F12 at 37°C for 3 days. After the three day culture, each well was observed under a phase-contrast

25

microscope in order to confirm the formation of cell clusters of the adipose stem cells.

[0105] As a result, as shown in Fig. 6, it was found that while at an early stage, the adipose stem cells proliferate while being adhered to the plate surface due to their biochemical interactions with the MBP-FGF recombinant protein having specific
5 adherent activity to the adipose stem cells, the adipose stem cells were detached from the plate surface to form a three-dimensional cell cluster as their density increased. In particular, in 10% FBS containing DMEM/F12, the formation of a cell cluster began one day after the culture and three days later, a spherical cell cluster having a diameter of about 800 μm was formed. In serum-free DMEM/F12, three days after the culture,
10 a cell cluster having a diameter of about 500 μm was formed. From the above results, it can be found that the immobilization of MBP-FGF recombinant proteins on the surface of a culture plate according to the present invention plays a key role in the formation of cell cluster of stem cells.

15 **Example 6: Induction of hypoxia inside the cell cluster**

[0106] In order to confirm that hypoxia inside the cell cluster was created by the formation of the cell cluster, the expression of HIF-1 α (hypoxia inducible factor-1 α) was examined by reverse transcriptase-PCR (RT-PCR). HIF-1 α , a representative
20 transcription factor that mediates the cellular response under hypoxic conditions, is known to be stabilized and activated under hypoxic conditions and to regulate the expression of several genes by binding to hypoxia response elements (HREs). Accordingly, the cell cluster was examined with respect to the expression of HIF-1 α , which is indicative of hypoxia in the cell. First, stem cells were cultured on a MBP-FGF recombinant protein-immobilized well plate in a FBS containing DMEM/F12
25 medium. Total RNA was isolated from cell clusters obtained one, two, and three days after the culture using the TRIzol reagent (Invitrogen, USA) and was used as a template

to synthesize cDNA using a Superscript II reverse transcriptase and an oligo (dT) primer. In order to confirm the expression of HIF-1 α using the synthesized cDNA as a template, polymerization was carried out using a primer pair having SEQ ID NOS: 2 and 3 (HIF-1 α sense: TGGACTCTCATCATCTGACC, HIF-1 α anti-sense: CTCAAGTTGCTGGTCATCAG). As a result, as shown in **Fig. 7**, it was confirmed that hypoxia was created inside the cell cluster, based on the expression of HIF-1 α in the cell cluster formed one day after culture.

Example 7: Increased production of angiogenic stimulators in the cell cluster

10 **[0107]** In order to confirm whether the hypoxia created in the cell cluster formed from stem cells enhances the production of angiogenic stimulators, the expression of angiogenesis related proteins was examined using an angiogenic protein analysis kit (Human Angiogenesis Array Kit, R&D Systems, Ltd.). Adipose stem cells cultured in a monolayer in a commercially available culture plate (control group) and those
15 cultured in the form of a cell cluster in a MBP-FGF recombinant protein-immobilized culture plate as in Example 5 above (Days 1 and 3) were harvested. Every 5×10^6 harvested cells were washed with PBS several times and then 500 μ l of the lysis buffer were added respectively. These cells were mixed using a pipette several times and subject to a reaction at 4 $^{\circ}$ C for 30 minutes to obtain a cell homogenate. The obtained
20 cell homogenate was subject to centrifugation (Combi-514R, Hanil) at 14,000 X g for 5 minutes to separate the supernatant in which proteins are dissolved and the concentration of the proteins was quantified. The supernatant separated above was allocated in an amount of 0.5 ml to each well of the 4-well multi-dish within the angiogenic protein analysis kit, followed by a reaction in the rocking platform for one
25 (1) hour with the addition of 2 ml of blot buffer and nitrocellulose membranes. On the nitrocellulose membrane, fifty-five (55) angiogenesis-related protein antibodies were

blotted as shown in **Fig. 8**. After the multi-dish was washed several times, 1.5 ml of biotin-conjugated antibodies were added to react at 4°C for about twelve (12) hours. After the completion of the reaction, the multi-dish was washed several times, followed by the addition of streptavidin-horseradish and 1.5 ml of chemiluminescent detection
5 reagents and a reaction in the darkroom for one (1) hour. After one hour, expression of the angiogenesis related proteins was observed using an image reader LAS-3000 (Fujifilm, Tokyo, Japan).

[0108] As a result, as shown in **Fig. 8**, in the cell cluster of adipose stem cells formed from the MBP-FGF recombinant protein-immobilized culture plate according to the
10 present invention, an overexpression of various angiogenesis-related proteins including VEGF, angiogenin, and IL-8 was detected, starting from one (1) day after the culture. The above results indicate that if stem cells are cultured in the form of a three-dimensional cell cluster according to the present invention, the formation of the cell cluster reduces the transmission of oxygen to the inside of the cluster, by which
15 hypoxia is created, and thus the production of various angiogenic stimulators affecting the differentiation of vascular endothelial cells is induced.

Example 8: Differentiation of stem cells in the cell cluster into vascular cells

[0109] As in Example 5, adipose stem cells were cultured in a culture plate on which a
20 MBP-FGF recombinant protein was immobilized at a concentration of 4×10^4 cells/cm² and the formed cell cluster was harvested. The harvested cell cluster was fixed at -70°C using an OCT compound and then cut into a thickness of 4 µm using a microtome. The fragment was fixed on a glass slide and immunologically stained. The immunological staining was carried out by soaking the glass slide prepared above in
25 PBS with a primary antibody to react overnight, followed by washing with PBS three times, and reacting with a secondary antibody in a dark room for one hour. After

termination of the reaction, the glass slide was washed with PBS three times, mounted and observed using flow cytometry.

[0110] As a result, a cell cluster of adipose stem cells formed in a MBP-FGF recombinant protein-immobilized culture plate according to the present invention exhibited a positive reaction with respect to CD29, CD34, KDR, CD31, and SMA, while exhibiting a negative reaction with respect to osteocalcin, nestin, and MAP-2. CD29 is a surface antigen which is specifically expressed on mesenchymal cells and epithelial cells, while CD34, KDR and CD31 are surface antigens specifically expressed on vascular endothelial cells. SMA is a cytoskeletal protein which is specifically expressed in smooth muscle cells. In addition, osteocalcin, nestin, and MAP-2 are proteins that are specifically expressed by bone cells and neural cells. Based on the above results, it was confirmed that a three-dimensional cell cluster formed by culturing adipose stem cells on a FGF-immobilized culture plate are composed of the vascular cells differentiated from the adipose stem cells.

[0111] **Fig. 9a** shows the results from CD29, CD34, KDR and CD31 immunological staining of the cell cluster formed from adipose stem cells in the presence of a serum containing medium on a growth factor-immobilized culture plate according to the present invention. **Fig. 9b** shows the results from immunological staining of the same cell cluster to SMA, nestin, and MAP-2. **Fig. 10** shows the results from CD31, CD34 and KDR immunological staining of the cell cluster formed from adipose stem cells in the presence of a serum-free medium on a growth factor-immobilized culture plate according to the present invention.

Example 9: Evaluation of angiogenesis by *in vivo* transplantation of the cell cluster

[0112] In order to evaluate the *in vivo* angiogenesis effect of the cell cluster composed of the vascular endothelial cells differentiated from stem cells according to the present

invention, 1×10^6 undifferentiated adipose stem cells isolated in Reference Example 1 or vascular cells differentiated from adipose stem cells constituting the cell cluster obtained in Example 5 were added in a solution comprising 500 μ l Matri-gel (BD Biosciences, main components: laminine, collagen type 4, heparin sulfate
5 proteoglycans (HSPG), and entactin/nidogen)) and 6 μ l fibrinogen (final concentration 2 mg/ml; Green Cross) to obtain a mixture, and then 2.5 μ l thrombin (0.4 U; Green Cross) was added to the mixture. The mixture prepared in the form of a gel was subcutaneously injected to four (4) week-old male BALB/c-nude mice (purchased from Central Lab. Animal Inc.) (*see* Fig. 11). The control group was injected with only 500
10 μ l of phosphate buffered saline (PBS). After the injection, the injection of the gel into the mice was confirmed with naked eyes and three weeks later, the mice were euthanized using nitrogen gas and then their skin was incised to recover the gel. The gel was examined to confirm angiogenesis by visual observation, immunological staining, and confocal microscopy.

15 **[0113]** As illustrated in **Fig. 11**, when observed with naked eyes, in the case where only a solution of Matri-gel/fibrin without injected cells was transplanted in the mice, the recovered gel was found to remain translucent. By comparison, when a solution of Matri-gel/fibrin injected with undifferentiated adipose stem cells was transplanted, the recovered gel was opaque and some angiogenesis was observed. In the case where
20 a solution of Matri-gel/fibrin injected with a cell cluster composed of the vascular cells differentiated from stem cells according to the present invention was transplanted, many red colored blood vessels were formed.

[0114] **Fig. 12** shows the results from the immunological staining of tissues removed from the nude mice which were injected with the Matri-gel/fibrin gel, using anti-human
25 CD31, CD34, KDR, and SMA antibodies. As a result, where only a solution of Matri-gel/fibrin was transplanted, neither CD31 nor SMA was stained. When a solution of

Matri-gel/fibrin injected with undifferentiated adipose stem cells was transplanted, there were a few cells which were positive to CD31 and SMA but no blood vessel-like structure was observed. On the other hand, in the case where a solution of Matri-gel/fibrin injected with a cell cluster composed of the vascular cells differentiated from stem cells according to the present invention was transplanted, the tissues were positive to all of CD31, CD34, KDR, and SMA, and blood vessel-like and tubular-shaped channels were observed. The above results indicate that the blood vessels formed in the nude mice were derived from a cell cluster composed of the vascular cells differentiated from stem cells, which was transplanted on the site where the blood vessels were formed.

Example 10: Evaluation of angiogenesis in ischemic rat models of the cell cluster

[0115] In order to evaluate whether the cell cluster composed of the vascular cells differentiated from stem cells according to the present invention exhibits a therapeutic effect for regeneration of blood vessels in ischemic animal models, Sprague-Dawley rats were anesthetized by ether inhalation. After shaving the lower legs and a skin incision, occlusion of the femoral artery was carried out to create ischemic conditions. Four (4) hours after the occlusion of the femoral artery in the lower legs, undifferentiated adipose stem cells isolated in Reference Example 1 or vascular cells differentiated from adipose stem cells constituting the cell cluster obtained in Example 5 were injected in the leg muscles of eight (8) ischemic rats at intervals of 0.5 cm diameter (5×10^6 cells per interval). As the control group, four (4) rats were injected with only PBS. At one (1) day, two (2) weeks, and four (4) weeks after the injection, the rats were examined for hypothermia. After four weeks, blood flow was imaged using a laser Doppler and quantitatively measured. After that, the rats were euthanized using nitrogen gas and then their lower legs under ischemia were removed.

The removed legs were examined by immunological staining for confirmation of angiogenesis.

[0116] As shown in **Fig. 13**, only the case where a cell cluster composed of the vascular cells differentiated from stem cells according to the present invention was transplanted was positive staining to anti-human CD31, SMA, and CD29 observed. As illustrated in **Fig. 14**, it can be found that in the case where a cell cluster composed of the vascular cells differentiated from stem cells according to the present invention was transplanted, the blood flow increased as compared to the control group or the case where adipose stem cells were transplanted. The above results indicate that a cell cluster composed of the vascular cells differentiated from stem cells according to the present invention can be effectively used in the treatment for the regeneration of ischemic lower limbs.

[0117] While the invention has been described in detail with respect to specific parts of the invention, it will be apparent to those skilled in the art that such descriptions are nothing more than exemplary embodiments of the invention and thus that the scope of the invention is not limited thereto.


BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT
OF MICROORGANISMS FOR THE PURPOSE OF PATENT PROCEDURE

INTERNATIONAL FORM

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT

issued pursuant to Rule 7.1

TO : KIM, Sang-Heon
Biomaterials Research Center, Korea Institute of Science and Technology
39-1 Hawolgok-dong, Seongbuk-gu, Seoul 136-791
Republic of Korea

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR: <i>Escherichia coli</i> K12 TB1/pMAL-bFGF	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: KCTC 11505BP
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
The microorganism identified under I above was accompanied by: <input checked="" type="checkbox"/> a scientific description <input type="checkbox"/> a proposed taxonomic designation (Mark with a cross where applicable)	
III. RECEIPT AND ACCEPTANCE	
This International Depositary Authority accepts the microorganism identified under I above, which was received by it on April 28, 2009 .	
IV. RECEIPT OF REQUEST FOR CONVERSION	
The microorganism identified under I above was received by this International Depositary Authority on _____ and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on _____	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: Korean Collection for Type Cultures Address: Korea Research Institute of Bioscience and Biotechnology (KRIBB) 111 Gwahangno, Yuseong-gu, Daejeon 305-806 Republic of Korea	Signature(s) of person(s) having the power to represent the International Depositary Authority of authorized official(s):  LEE, Jung-Suk, Director Date: May 6, 2009

WHAT IS CLAIMED:

1. A method of differentiating stem cells into vascular cells comprising:
adhering stem cells onto a culture plate having a surface with a
5 hydrophobic property, wherein the adhered stem cells are later detached from the
culture plate as their density increases to form a three-dimensional cell cluster and are
grown in the form of a three-dimensional cell cluster while differentiating into vascular
cells.
- 10 2. The method according to Claim 1, wherein the stem cells are selected
from the group consisting of adipose stem cells, mesenchymal stem cells, bone marrow
stem cells, umbilical cord blood stem cells, neural stem cells, and induced pluripotent
stem cells.
- 15 3. The method according to Claim 1, wherein the stem cells are
inoculated at a concentration of 1×10^4 to 3×10^5 cells/cm².
4. The method according to Claim 1, wherein the culture plate has a
surface selected from the group consisting of a silanized surface, a hydrocarbon coated
20 surface, a polymer surface, and a metal surface.
5. The method according to Claim 4, wherein said polymer is selected
from the group consisting of polystyrene, polymethylmethacrylate (PMMA),
polyethylene terephthalate (PET), polyvinylchloride (PVC), polyethylene (PE),
25 polypropylene (PP), polytetrafluoroethylene (PTFE), poly(L-lactic acid) (PLLA),
poly(D,L-lactic acid) (PDLLA), poly(glycolic acid) (PGA), poly(caprolactone) (PCL),

poly(hydroxyalkanoate), polydioxanone (PDS), polytrimethylencarbonate, and copolymers and derivatives thereof.

6. The method according to Claim 4, wherein said metal is selected from
5 the group consisting of stainless steel, titanium, gold, and platinum.

7. The method according to Claim 1, wherein the stem cells are adhered
to the culture plate by cell-matrix interactions with the surface with a hydrophobic
property or by interactions with a growth factor immobilized on the surface of the
10 culture plate, said growth factor having an adherent activity to said stem cells.

8. The method according to Claim 7, wherein said growth factor is
selected from the group consisting of vascular endothelial growth factor (VEGF),
fibroblast growth factor (FGF), epidermal growth factor (EGF), platelet-derived
15 endothelial growth factor (PDGF), hepatocyte growth factor (HGF), insulin-like growth
factor (IGF), and heparin binding domain (HBD).

9. The method according to Claim 7, wherein said growth factor is
immobilized on the surface of the culture plate at a concentration of 5 to 100 µg/ml.

20

10. The method according to Claim 7, wherein said growth factor is
immobilized on the surface of the culture plate using a polypeptide linker in the form of
a polypeptide linker-growth factor recombinant protein in which an amino terminal
group of the growth factor is fused to a carboxy terminal group of the polypeptide
25 linker.

11. The method according to Claim 10, wherein said polypeptide linker is selected from the group consisting of maltose-binding protein (MBP), hydrophobin, and hydrophobic cell penetrating peptides (CPPs).

5 12. The method according to Claim 10, wherein, in the polypeptide linker-growth factor recombinant protein, an amino terminal group of a fibroblast growth factor (FGF) is fused to a carboxyl terminal group of a maltose binding protein (MBP) and wherein said polypeptide linker-growth factor recombinant protein has an amino acid sequence of **SEQ ID NO: 1**.

10

13. The method according to Claim 1, wherein the stem cells cultured in step 2 are detached from the culture plate to form a three-dimensional cell cluster as the density of the stem cells increase so that intercellular interactions are stronger than cell-matrix interactions.

15

14. The method according to Claim 1, wherein in step 3, hypoxia is created inside the three-dimensional cell cluster and production of angiogenic stimulators increases, whereby the stem cells differentiate into vascular cells.

20 15. The method according to Claim 1, wherein the three-dimensional cell cluster has a diameter of 400 μm to 1 mm and is composed of the vascular cells differentiated from stem cells.

25 16. The method according to Claim 1, wherein in step 1, in the case where the stem cells are adhered to the culture plate by cell-matrix interactions with the surface with a hydrophobic property, the culture of the cells is carried out at a

temperature in the range of 35 to 38.5°C and for 1 to 7 days.

17. The method according to Claim 1, wherein in step 1, in the case where the stem cells are adhered to the culture plate by interactions with a growth factor
5 immobilized on the surface of the culture plate, said growth factor having an adherent activity to said stem cells, culturing in steps 1 to 3 is conducted at a temperature in the range of 35 °C to 38.5°C and for 1 to 7 days.

18. A three-dimensional cell cluster composed of vascular cells which
10 have been differentiated from stem cells.

19. The three-dimensional cell cluster according to Claim 18, wherein the stem cells are selected from the group consisting of adipose stem cells, mesenchymal stem cells, bone marrow stem cells, umbilical cord blood stem cells, neural stem cells,
15 and induced pluripotent stem cells.

20. The three-dimensional cell cluster according to Claim 18, wherein hypoxia is created inside the three-dimensional cell cluster.

20 21. The three-dimensional cell cluster according to Claim 18, wherein the cell cluster has a diameter of 400 μm to 1 mm.

22. The three-dimensional cell cluster according to Claim 18, wherein the differentiated vascular cells comprise vascular endothelial cells and smooth muscle
25 cells.

23. A cell therapy composition for the treatment of vascular diseases or wounds, which contains as active ingredients, a cell cluster formed by the method of Claim 1 and a culture medium.

5 24. The cell therapy composition according to Claim 23, wherein said vascular disease is a cardiovascular disease, cerebrovascular disease, or ischemic disease.

10 25. The cell therapy composition according to Claim 23, wherein said vascular disease is selected from the group consisting of atherosclerosis, angina pectoris, peripheral cardiovascular disease, hypertension, heart failure, peripheral circulatory disturbance, myocardial infarction, stroke, ischemic attack, and subarachnoid hemorrhage.

15 26. A tissue engineering composite scaffold for regeneration of blood vessels, wherein a cell cluster formed by the method of Claim 1 is loaded on a biodegradable scaffold.


20 27. The tissue engineering composite scaffold according to Claim 26, wherein said biodegradable scaffold is made of a material selected from the group consisting of fibrin, collagen, gelatin, chitosan, alginate, hyaluronic acid, dextran, polylactic acid, poly(glycolic acid (PGA)), poly(lactic acid-co-glycolic acid), poly(lactic acid-co-glycolic acid (PLGA)), poly- ϵ -(caprolactone), polyanhydride, polyorthoester, polyvinylalcohol, polyethyleneglycol, polyurethane, polyacrylic acid, poly-N-
25 isopropylacrylamide, poly(ethyleneoxide)-poly(propyleneoxide)-poly(ethyleneoxide) copolymers, and copolymers and mixtures thereof.

28. The tissue engineering composite scaffold according to Claim 26, wherein said cell cluster is loaded on the scaffold at a concentration of 2×10^4 to 3×10^5 cells/cm² based on the vascular cells constituting the cell cluster.


5

DRAWINGS


【Fig. 1a】




【Fig. 1b】




【Fig. 2】




【Fig. 3】




【Fig. 4】




【Fig. 5】




【Fig. 6】




【Fig. 7】




【Fig. 8】




【Fig. 9a】




【Fig. 9b】




【Fig. 10】




【Fig. 11】



【Fig. 12】



【Fig. 13】



【Fig. 14】

